Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is characterized by high malignancy, strong invasiveness, and a propensity for distant metastasis, leading to poor prognosis and relatively limited treatment options. Metformin, as a first-line oral hypoglycemic agent, has garnered widespread research interest in recent years due to its potential in cancer prevention and treatment. However, its efficacy varies significantly across different tumor types. Histone deacetylase inhibitors (HDACi), such as SAHA, have demonstrated antitumor activity, but TNBC responds poorly to HDACi monotherapy, possibly due to feedback activation of the JAK-STAT pathway. Exploring the synergistic potential and underlying mechanisms of combining metformin with HDACi in TNBC treatment is crucial.

Methods<

SUBMITTER: Gu Z 

PROVIDER: S-EPMC11912690 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature